行情

CHMA

CHMA

Chiasma
NASDAQ

实时行情|Nasdaq Last Sale

4.630
-0.120
-2.53%
盘后: 4.630 0 0.00% 16:00 01/24 EST
开盘
4.760
昨收
4.750
最高
4.800
最低
4.560
成交量
20.48万
成交额
--
52周最高
9.25
52周最低
3.300
市值
1.95亿
市盈率(TTM)
-4.0768
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CHMA 新闻

  • Does Chiasma, Inc. (NASDAQ:CHMA) Have A High Beta?
  • Simply Wall St..2小时前
  • 微博2020让红包飞集卡玩出新高度 超14亿人次参与
  • 新浪科技.4小时前
  • 美国将对进口钢铝衍生品加征关税
  • 新华网.5小时前
  • 玩游戏了解流行病?单机游戏“瘟疫公司”多国畅销
  • 新京报网.6小时前

更多

所属板块

制药
-1.84%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

CHMA 简况

Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company's TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.
展开

Webull提供Chiasma Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。